Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Upgraded at Wall Street Zen

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Saturday.

Other research analysts have also recently issued reports about the company. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. UBS Group cut Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock opened at $23.51 on Friday. Fresenius Medical Care AG & Co. KGaA has a 1-year low of $22.05 and a 1-year high of $30.46. The company has a 50-day moving average of $24.67 and a two-hundred day moving average of $25.75. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 0.45.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%. The business had revenue of $5.73 billion for the quarter, compared to the consensus estimate of $4.72 billion. Equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% in the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock valued at $32,000 after purchasing an additional 1,040 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth $36,000. CIBC Private Wealth Group LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares in the last quarter. Atlantic Union Bankshares Corp purchased a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at $43,000. Finally, Hantz Financial Services Inc. raised its stake in Fresenius Medical Care AG & Co. KGaA by 568.5% in the second quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock valued at $59,000 after buying an additional 1,768 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.